Over the past decade, several novel immunotherapies have transformed the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukaemia. In the pivotal TOWER trial, blinatumomab—a ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

A recent webinar from BD shared important insights into patient fear and anxiety over self-injection and how the right device ...

In patients with inborn errors of immunity who are prone to viral infections, immunoglobulin replacement therapy (IRT) administered via the conventional subcutaneous route showed lower viral infection ...

The U.S. Food and Drug Administration (FDA) this week approved GSK‘s 200 mg/mL autoinjector of Benlysta (belimumab) for use ...

The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for children aged 5 years of older with active lupus nephritis (LN) who are receiving standard therapy.

The FDA has approved a 200 mg/mL autoinjector of belimumab (Benlysta) for at-home subcutaneous use in children aged 5 years ...

The US FDA has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five years and above with active lupus ...

Children with diabetes who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the ...

GSK’s approval expands belimumab treatment options, offering a first-of-its-kind subcutaneous option that can be administered ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...